1. Home
  2. ASRT vs IKNA Comparison

ASRT vs IKNA Comparison

Compare ASRT & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASRT
  • IKNA
  • Stock Information
  • Founded
  • ASRT 1995
  • IKNA 2016
  • Country
  • ASRT United States
  • IKNA United States
  • Employees
  • ASRT N/A
  • IKNA N/A
  • Industry
  • ASRT Biotechnology: Pharmaceutical Preparations
  • IKNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ASRT Health Care
  • IKNA Health Care
  • Exchange
  • ASRT Nasdaq
  • IKNA Nasdaq
  • Market Cap
  • ASRT 78.3M
  • IKNA 81.6M
  • IPO Year
  • ASRT 1997
  • IKNA 2021
  • Fundamental
  • Price
  • ASRT $0.86
  • IKNA $1.54
  • Analyst Decision
  • ASRT Strong Buy
  • IKNA Buy
  • Analyst Count
  • ASRT 4
  • IKNA 2
  • Target Price
  • ASRT $3.19
  • IKNA $3.00
  • AVG Volume (30 Days)
  • ASRT 327.3K
  • IKNA 169.4K
  • Earning Date
  • ASRT 03-10-2025
  • IKNA 03-11-2025
  • Dividend Yield
  • ASRT N/A
  • IKNA N/A
  • EPS Growth
  • ASRT N/A
  • IKNA N/A
  • EPS
  • ASRT N/A
  • IKNA N/A
  • Revenue
  • ASRT $125,763,000.00
  • IKNA $659,000.00
  • Revenue This Year
  • ASRT N/A
  • IKNA N/A
  • Revenue Next Year
  • ASRT $1.84
  • IKNA N/A
  • P/E Ratio
  • ASRT N/A
  • IKNA N/A
  • Revenue Growth
  • ASRT N/A
  • IKNA N/A
  • 52 Week Low
  • ASRT $0.73
  • IKNA $1.22
  • 52 Week High
  • ASRT $1.80
  • IKNA $1.94
  • Technical
  • Relative Strength Index (RSI)
  • ASRT 53.75
  • IKNA 44.03
  • Support Level
  • ASRT $0.78
  • IKNA $1.40
  • Resistance Level
  • ASRT $0.88
  • IKNA $1.47
  • Average True Range (ATR)
  • ASRT 0.03
  • IKNA 0.05
  • MACD
  • ASRT 0.01
  • IKNA 0.01
  • Stochastic Oscillator
  • ASRT 75.00
  • IKNA 53.57

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Share on Social Networks: